NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · FDMT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
4D Molecular Therapeutics, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$1.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow 4D Molecular Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.86-2.38% vs estimate | $14.00K-97.4% vs estimate |
|---|
| Q4 2024 | Feb 28, 2025 | -$0.90-12.5% vs estimate | $1.00K-99.96% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.79-17.91% vs estimate | $3.00K-99.86% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $32.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$25.30+$0.33 (+1.32%)
uniQure N.V.’s quoted price sits in the lower half of its reported 52-week range, 63.85% below the high.
$9.71-$0.05 (-0.46%)
MeiraGTx Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 36.78% below the high.
$6.39-$0.09 (-1.39%)
Solid Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
$7.41+$0.17 (+2.35%)
REGENXBIO Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.23% below the high.
$4.56+$0.01 (+0.22%)
Abeona Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.39% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
$3.06-$0.07 (-2.24%)
Lexeo Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 72.16% below the high.
